Country | Qualification criteria (Q1-Q5) % (n) | Diagnosis (Q6-Q13) % (n) | Therapy (Q14-Q20) % (n) | NTM-PD Impact (Q21-Q30) % (n) | Final demographics/ comorbidity (Q31-Q33) % (n) |
---|---|---|---|---|---|
United Kingdom | 100.0% (185) | 44.9% (83) | 38.9% (72) | 35.1% (65) | 35.1% (65) |
Germany | 100.0% (111) | 69.4% (77) | 65.8% (73) | 64.9% (72) | 64.9% (72) |
Italy | 100.0% (87) | 73.6% (64) | 66.7% (58) | 62.1% (54) | 60.9% (53) |
France | 100.0% (56) | 75.0% (42) | 64.3% (36) | 60.7% (34) | 58.9% (33) |
Spain | 100.0% (38) | 55.3% (21) | 36.8% (14) | 31.6% (12) | 28.9% (11) |
Belgium | 100.0% (33) | 69.7% (23) | 60.6% (20) | 57.6% (19) | 57.6% (19) |
The Netherlands | 100.0% (22) | 59.1% (13) | 50.0% (11) | 50.0% (11) | 50.0% (11) |
Austria | 100.0% (11) | 45.5% (5) | 36.4% (4) | 36.4% (4) | 36.4% (4) |
Total | 100.0% (543) | 60.4% (328) | 53.0% (288) | 49.9% (271) | 49.4% (268) |